View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 16, 2022

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

The mRNA-1273.214 comprises mRNA-1273 and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1 Omicron variant of concern.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional authorisation for Moderna’s Covid-19 booster vaccine, mRNA-1273.214 (Spikevax Bivalent Original/Omicron), for use in adults aged 18 years and above.

The updated, Omicron-containing bivalent vaccine that acts on two coronavirus variants is indicated as a booster dose for active immunisation for the prevention of Covid-19 in people of this age group.

It comprises mRNA-1273 (Spikevax) and a vaccine candidate that acts on the SARS-CoV-2 virus’ BA.1 Omicron variant of concern.

After the vaccine was found to meet the standards of safety and quality, the regulatory agency granted the authorisation.

The latest MHRA decision is based on findings from the Phase II/III clinical trial, where the mRNA-1273.214 vaccine met all primary endpoints.

In baseline seronegative subjects, the updated vaccine offered a superior neutralising antibody response against Omicron (BA.1) versus the 50µg mRNA-1273 booster dose.

Furthermore, neutralising geometric mean titers (GMT) against Omicron rose by nearly eight-fold above baseline levels following dosing with the booster shot of mRNA-1273.214. 

Irrespective of previous infection or age, the vaccine-induced potent neutralising antibody responses against the BA.4 and BA.5 Omicron subvariants versus the presently authorised booster of mRNA-1273.

According to the safety monitoring, side effects were generally mild and self-resolving, as well as in line with those reported for the original Moderna booster dose.

In addition, no serious safety concerns linked to the vaccine were observed.

MHRA chief executive Dr June Raine said: “I am pleased to announce the approval of the Moderna bivalent booster vaccine, which was found in the clinical trial to provide a strong immune response against the Omicron BA.1 variant as well as the original 2020 strain.”

In June, Moderna signed an agreement in principle with the UK Government to build a new mRNA vaccine manufacturing facility in the country.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Optimise your cell therapy process: a guide to cell thawing

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology